M2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s.

Li, Jianquan; Dang, Nanmao; Martinez-Lopez, Nuria; Jowsey, Paul A; Huang, Dong; Lightowlers, Robert N; Gao, Fei; Huang, Jun-Yong.

Afiliação

Li J; 1Institute for Cell and Molecular Biosciences, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH UK.
Dang N; 3Present Address: Intensive Care Unit, Guizhou Provincial People's Hospital, Guiyang, People's Republic of China.
Martinez-Lopez N; 1Institute for Cell and Molecular Biosciences, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH UK.
Jowsey PA; 1Institute for Cell and Molecular Biosciences, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH UK.
Huang D; 2Medical Toxicology Centre, Institute of Cellular Medicine, NIHR Health Protection Research Unit, Newcastle University, Claremont Place, Newcastle upon Tyne, NE1 4AA UK.
Lightowlers RN; 1Institute for Cell and Molecular Biosciences, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH UK.
Gao F; 4Present Address: Department of Pediatric Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang, People's Republic of China.
Huang JY; 1Institute for Cell and Molecular Biosciences, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH UK.

Cell Div ; 14: 5, 2019.

Article em En | MEDLINE | ID: mdl-31249607